I've raised this because, actually, we have a similar problem right across our regulatory regimes, and it's been very true during COVID in our response to it. It's been true across medicines. The fact that we need this bespoke legislation so we can approve something that other countries have been doing for months—that is, giving a fourth dose—tells us that our regulatory system is duplicative and broken, and we need to fix that. But, actually, we need to fix our regulatory systems and duplication thereof right across the board when it comes to product markets. 